Rodney Bucher, MD
Retina Specialist · Carmel, INNPI 1639173131
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (55.9%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 97.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $21,333 and has fallen 99.9% since, to $21 in 2025.
Across 31 payments — averaging $959.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$29K
- Coherus Oncology, Inc.$205
- Alimera Sciences, Inc.$86
- Regeneron Healthcare Solutions, Inc.$78
- Genentech USA, Inc.$73
- Astellas Pharma US Inc$43
- plus $128 from 7 others
What the payments were for
- Food & beverage$6142%
- Ownership interest$12,48742%
- Other$16,62956%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $29,117 |
| Coherus Oncology, Inc. | 2 | $205 |
| Alimera Sciences, Inc. | 4 | $86 |
| Regeneron Healthcare Solutions, Inc. | 4 | $78 |
| Genentech USA, Inc. | 4 | $73 |
| Astellas Pharma US Inc | 2 | $43 |
| Biogen | 2 | $36 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Alcon | 1 | $15 |
| AbbVie | 1 | $14 |
| Novartis | 1 | $14 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cimerli$124
How this compares
$29,730 in reported general payments places this provider in the 80th percentile of 21 retina specialist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 222 | $8,842 |
| MoxifloxacinMoxifloxacin Hcl | 88 | $2,484 |
| Difluprednate | 42 | $2,157 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,139 |
| Ketorolac Tromethamine | 51 | $1,086 |
| ErythromycinErythromycin Base | 46 | $557 |
| Dorzolamide Hcl | 25 | $489 |
| Timolol Maleate | 50 | $402 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $401 |
| Brimonidine Tartrate | 20 | $209 |
| Prednisone | 57 | $172 |
| Latanoprost | 14 | $33 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Carmel
- Ankur ShahCarmel$569K
- Raj MaturiCarmel$100K
- Ramana MoorthyCarmel$61K
- Milan ShahCarmel$35K
- Julia HudsonCarmel$3K
- Stephen SaxeCarmel$610
- Frederick PrallCarmel$475
- Mark KaehrCarmel$451
- John MinturnCarmel$133
- Denis JusufbegovicCarmel$123
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.